Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

Department of Thoracic Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230-1402, USA.
Cancer (Impact Factor: 4.89). 01/2006; 106(2):366-74.
Source: PubMed


Small cell lung carcinoma (SCLC) cell lines commonly express KIT and its ligand, stem cell factor, suggesting an autocrine loop promoting cell growth. Imatinib inhibits KIT kinase activity. SCLC cells treated with imatinib in vitro undergo cell cycle arrest. Imatinib reduces resistance to irinotecan in vitro. Common metabolic pathways suggest there may be drug interactions between imatinib and irinotecan or cisplatin. In the current study, the authors investigated the feasibility of combining these drugs in the treatment of patients with SCLC.
Two Phase I studies were conducted independently at two institutions. Patients with extensive-disease SCLC underwent therapy with cisplatin, irinotecan, and imatinib using two similar regimens. In one study, immunohistochemical analysis of the expression of potential imatinib targets was performed on pretreatment biopsy specimens, and blood specimens were collected and analyzed for imatinib, irinotecan, and cisplatin pharmacokinetic parameters.
Nine patients were enrolled and were evaluable for toxicity. A high incidence of neutropenia, diarrhea, and thrombosis was observed that precluded dose escalation. Six patients were evaluable for response after four cycles; five patients experienced a partial response and the other patient had developed progressive disease. Four of six tumor specimens tested expressed platelet-derived growth factor receptor-alpha and two expressed KIT. Irinotecan clearance was found to be significantly decreased by imatinib (P < 0.04). No significant alteration in the disposition of cisplatin was observed.
The maximum tolerated dose for this combination with granulocyte-colony-stimulating factor support was identified as imatinib at a dose of 300 mg/day with irinotecan (at a dose of 65 mg/m(2)) and cisplatin (at a dose of 30 mg/m(2)) given on Days 1 and 8, every 21 days. The decreased irinotecan clearance may explain the high incidence of diarrhea and neutropenia noted in the current study.

Download full-text


Available from: Faye M Johnson, Sep 25, 2014
  • Source
    • "In combination with irinotecan and cisplatin chemotherapy, imatinib also failed to demonstrate improvement in overall response rate and survival. Moreover, the combination was toxic with an increase in grade 3—4 neutropenia and diarrhoea, possibly due to impaired clearance of irinotecan in the presence of imatinib [Johnson et al. 2006]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease.
    Full-text · Article · Jan 2010 · rapeutic Advances in Medical Oncology, The

  • No preview · Article · Dec 2003 · Heart, Lung and Circulation
  • [Show abstract] [Hide abstract]
    ABSTRACT: Imatinib mesilate is a tyrosine kinase inhibitor that has been shown to be highly effective in the treatment of malignancies, such as chronic myeloid leukaemia and gastrointestinal stromal tumours that are characterised by specific molecular defects towards which this drug is targeted. The authors briefly review selected preclinical and clinical data concerning the use of imatinib in some common solid tumour types, concluding that the biological and clinical impact still needs to be further elucidated. Imatinib represents a promising therapeutic option with far less toxicity than traditional approaches, although integrated, multimodality approaches, including surgery, will remain of value in the era of molecularly targeted therapy.
    No preview · Article · Oct 2006 · Expert Opinion on Therapeutic Patents
Show more